235 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1752)
- Addiction (19)
- Allergy, Asthma, & Immunology (13)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (29)
- Blood Disorders (33)
- Bone & Muscle (10)
- Cancer
(564)
- (-) Bladder Cancer (13)
- Brain Cancer (12)
- Breast Cancer (60)
- Gastrointestinal (10)
- Gynecologic Cancer (30)
- Head and Neck Cancer (4)
- Kidney Cancer (7)
- Leukemia (64)
- Liver Cancer (4)
- Lung Cancer (57)
- Lymphoma (24)
- Multiple Myeloma (24)
- Pancreatic Cancer (6)
- Prostate Cancer (25)
- Sarcoma (23)
- Skin Cancer (26)
- Solid Tumors (36)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (21)
- Ear, Nose and Throat (12)
- Endocrine & Metabolic Disease (12)
- Eye (7)
- Gastrointestinal and Digestive Diseases (26)
- Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (187)
- Heart Disease (130)
- Infectious Disease (49)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (53)
- Lung Disease (31)
- Meniere's Disease (1)
- Neurological Disorders (165)
- Nutrition (5)
- Obesity (10)
- Obstetrics & Gynecology (55)
- Pain Management (1)
- Pediatrics (103)
- Psychiatric Disorders (67)
- Rehabilitation (9)
- Stroke (7)
- Surgery (7)
- Transplant (48)
- Urology (4)
- Vascular Conditions (10)
Displaying 1 - 29 of 29
Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is to determine whether using LY4052031 in a type of cancer that may have tumor cells that express a protein called Nectin-4 is safe and how well the cancer responds to the study drug. LY4052031 has not been approved by the US Food and Drug Administration (FDA). This is a first in human study and all of the risks are not fully…
Condition: Neurological Disorders / Dementia
Investigator: Justin Golub, MD, MS
Status: Currently Recruiting
Early Age-Related Hearing Loss Investigation (EARHLI) is a study to obtain information on how a hearing aid-based intervention can prevent cognitive decline in those at risk for Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). Age-related hearing loss (ARHL) is the third most common chronic condition in older adults. The…
Condition: Neurological Disorders / Dementia
Investigator: Christiane Reitz, MD, PhD
Status: Currently Recruiting
We are recruiting individuals and/or families with members under the age of 65 who have dementia or are experiencing memory problems. Our initial screening can be completed in person or over the phone. The evaluation will take about 1 to 1.5 hours per person and includes a: 1. Blood sample (5 tablespoons) or saliva (1 teaspoon) collection: These blood…
Condition: Neurological Disorders / Dementia
Investigator: Scott Small, MD
Status: Currently Recruiting
For over 30 years, The Columbia University Alzheimer's Disease Research Center (ADRC) has worked with thousands of participants who have helped provide important insights into how the brain ages and why Alzheimer's disease may develop. We are actively recruiting adults 65 years of age and older who share our commitment to be part of this…
Condition: Cancer / Bladder Cancer
Investigator: Andrew Lenis, MD
Status: Closed
This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual therapy? The usual approach for patients who are not in a study is treatment with Transurethral surgery of bladder tumor (…
Condition: Neurological Disorders / Dementia
Investigator: Sairam Geethanath, PhD
Status: Closed
A significant focus of healthcare research is aimed at biomarker discoveries in brain and heart diseases in particular, and their impact on the human body in general. MRI is a key component in these healthcare services. It provides a non-invasive and non-ionizing approach to diagnose pathologies along with significant internal and external contrast…
Condition: Neurological Disorders / Dementia
Investigator: Lawrence Honig, MD, PhD
Status: Closed
This study is of a drug called CT1812, that is being evaluated as a possible treatment for Dementia with Lewy Bodies. In this study, which is carried out at multiple sites in the country, participants receive either CT1812 at one of two doses or placebo. The duration of the study is up to about 35 weeks. Participants receive blood tests, cerebrospinal fluid…
Condition: Neurological Disorders / Dementia
Investigator: Lawrence Honig, MD, PhD
Status: Closed
This is a research study for persons with memory problems that examines the utility of performing positron emission tomography (PET) scans for the brain amyloid protein found in Alzheimer's disease.
Condition: Cancer / Bladder Cancer
Investigator: Christopher Anderson, MD
Status: Closed
This study is for patients who have bladder cancer that has not invaded muscle tissue and who have been treated with one or more surgical resections and Bacillus Calmette-Guerin or BCG, which was directly given into the bladder before. The main purpose of this trial is to show that durvalumab is safe when given alone, in combination with BCG treatments, and…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
We are doing this research to find out the safety, toxicity, and efficacy of intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of non-muscle-invasive urothelial carcinoma of the bladder that has recurred despite BCG use. The purpose of finding the maximum tolerable dose is important for future use of the drug, so as to provide the…
Condition: Neurological Disorders / Dementia
Investigator: Edward Huey, MD
Status: Closed
Columbia Medical Center is recruiting for a study to test whether the drug oxytocin can improve symptoms of emotion and behavior (e.g. apathy) in people with frontotemporal dementia. The study will last for up to 24 weeks (6 months). This is a crossover study, which means that each participant will receive both oxytocin and placebo (medically inactive…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This is a Phase 1 study (the first time this treatment is being tested in humans) of an anti-cancer study drug called as PF-07225570. This study drug works on stimulating certain cells in the immune system. The study will test different doses that increase (dose escalation) and at the appropriate time, additional patients will be enrolled to evaluate this…
Condition: Heart Disease / Arterial Disease
Investigator: Robert Sommer, MD
Status: Closed
This is a prospective, single arm, three stage, multi-site, clinical investigation evaluating the safety and efficacy of the Carag Bioresorbable Septal Occluder (CBSO) to treat patients with clinically significant hole in the atrial septal defect compared to other commercially approved devices. The study is being done to determine the safety and efficacy of…
Condition: Heart Disease / Arterial Disease
Investigator: Robert Sommer, MD
Status: Closed
This prospective, multicenter, open-label, single arm, first-in human study will enroll up to 75 subjects aimed at examining the performance of the LAAC device for LAA closure.
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This research study will investigate an experimental, unapproved drug that will be given two different ways; as an injection in the bladder wall after bladder tumor resection surgery (or TURBT) and then as an intravesical instillation (fluid inserted in the bladder by catheter) right after the injection. The purpose of this study is to find the dose which…
Condition: Cancer / Bladder Cancer
Investigator: Mark Stein, MD
Status: Closed
This clinical trial is for patients who have cancer of the urinary system (urothelial cancer, including cancer of the bladder, renal pelvis, ureter or urethra) that has spread to nearby tissues or to other areas of the body who have already been treated with a kind of anticancer drug called an immune checkpoint inhibitor (CPI). This clinical trial uses an…
Condition: Heart Disease / Arterial Disease
Investigator: Susheel Kodali, MD
Status: Closed
The purpose of this research study, is to learn whether an experimental device (called Evolut R) can help clear hardened blockage in coronary arteries (blood vessels that feed the heart muscle) in patients with a disease is called aortic stenosis.Subjects that choose to participate and are eligible will have their interventional cardiologist use this device…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The purpose of this study is to look at a new treatment for non-muscle-invasive bladder cancer. This new form of paclitaxel, a drug currently used by injection into a vein to treat various types of cancer, is designed to be instilled (injected) into the urinary bladder with a catheter (tube) placed into your bladder through your urethra (the opening where…
Condition: Heart Disease / Arterial Disease
Investigator: Melvin Weiss, MD, FACC
Status: Closed
The purpose of this study is to see if a new medication called ticagrelor given twice daily ismore effective than aspirin alone in preventing the occurrence of heart attack, stroke and/ordeath due to cardiovascular events in patients who have type 2 diabetes. Ticagrelor is anantiplatelet therapy (stop platelets from clumping together) and is approved for…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This study is being conducted to evaluate the performance of the AssureMDx test for the detection of bladder cancer in patients presenting with hematuria.
Condition: Heart Disease / Arterial Disease
Investigator: Tamim Nazif, MD
Status: Closed
The purpose of this study is to survey patients who have undergone a percutaneous coronary intervention (PCI) at Columbia University Medical Center in which the physician used a stent called the Promus Premier stent. Patients will be asked to do a brief 15-30 minute survey regarding their health since the PCI and stent implantation.
Condition: Neurological Disorders / Dementia
Investigator: Lawrence Honig, MD, PhD
Status: Closed
This is a 22-week treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 2 study to evaluate the efficacy, safety, and tolerability of the study drug E2027, in participants with Dementia with Lewy Bodies (DLB) Lewy Body Dementia - LBD. The main purpose of this research study is to find if a new drug called E2027 works in people who…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The purposes of this clinical study are: To evaluate the safety and tolerability of up to 2 drug release periods of GemRIS for up to 7 days per drug release period To evaluate the pharmacokinetics (the study of the bodily absorption, distribution, metabolism, and excretion of the drug) of gemcitabine and a gemcitabine-related metabolite (product after…
Condition: Heart Disease / Arterial Disease
Investigator: Kumar Kalapatapu, MD, FACC
Status: Closed
The purpose of this study is to evaluate the Biosensors BioFreedom Biolimus A9 Drug Coated Coronary Stent on people with coronary artery disease (blockages in the heart arteries) to determine if it is safe and effective.
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The study is part of a research program to assess the efficacy of the drug nab-rapamycin, a biologic mTOR inhibitor. The purpose of the study is to assess the response rate, as well as, the safety of administering nab-rapamycin in combination with gemcitabine directly into the bladder in an effort to treat bladder cancer. The study seeks to determine if…
Condition: Cancer / Bladder Cancer
Investigator: Christopher Anderson, MD
Status: Closed
This research is being done to study the effects, safety, and tolerability of the study drugs Nivolumab and Urelumab when given to people with advanced bladder cancer that has spread into the muscle tissue, also called Muscle-Invasive Urothelial Carcinoma of the Bladder (MIBC). Specifically, this research study will have participants either take Nivolumab…
Condition: Heart Disease / Arterial Disease
Investigator: Manish Parikh, MD
Status: Closed
The purpose of this research is to find out whether it is safe to shorten the length of time that people at high risk for bleeding take blood thinners after being treated with a coronary stent.
Condition: Cancer / Bladder Cancer
Investigator: Emerson Lim, MD
Status: Closed
The purpose of this study is to test how well the drug works, safety, and side effects of the experimental drug called BMS-986205. BMS-986205 will be added to another cancer medicine called nivolumab plus chemotherapy for participants who have bladder cancer that has grown into the muscle wall of the bladder. These drugs will be compared to just…
Condition: Heart Disease / Arterial Disease
Investigator: Michael Collins, MD
Status: Closed
This study is for patients with Coronary Artery Disease (CAD) and require a stent placement. The purpose of this clinical research study is to assess the safety and effectiveness of the Orsiro stent or a non-investigational Xience stent. The Orsiro stent is investigational, which means it is not yet approved by the FDA and can only be used in research…